Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy

With the emergence of effective immunotherapeutics, which nevertheless harbor the potential for toxicity and are expensive to use, biomarkers are urgently needed for identification of cancer patients who respond to treatment. In this clinical-epidemiological study of 202 cancer patients treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Liikanen, Ilkka, Koski, Anniina, Merisalo-Soikkeli, Maiju, Hemminki, Otto, Oksanen, Minna, Kairemo, Kalevi, Joensuu, Timo, Kanerva, Anna, Hemminki, Akseli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404794/
https://www.ncbi.nlm.nih.gov/pubmed/25949903
http://dx.doi.org/10.4161/2162402X.2014.989771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404794/
https://www.ncbi.nlm.nih.gov/pubmed/25949903
http://dx.doi.org/10.4161/2162402X.2014.989771

Ejemplares similares